Delivery Order SPE2DB22D9239-SPE2DB25FDD63
Award Date
10/4/24
Potential Completion Date
10/28/24
Potential Value
$40K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $120,428.55 to provide 4,566,597,117 units of Keytruda 100 mg/4 ml vial. The contract is a firm fixed-price award from the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of December 20, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of Keytruda 100 mg/4 ml vial 4 ml to the U.S. government. The contract, valued at $48,171.42, is a firm fixed-price delivery order with no set-aside designation, awarded by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $80,218.40, is for the delivery of Keytruda 100 mg/4 ml vials. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA, valued up to $499,999,999, which allows the agency to issue firm fixed-price delivery orders for a comprehensive...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of Keytruda 100 mg/4 ml vials. The $48,171.42 firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA), a defense agency, on August 8, 2024, with a completion date of August 29, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $40,142.85, is for the delivery of Keytruda 100 mg/4 ml vials to support the recurring medical supply needs of military health facilities. The contract has a completion date of June 25, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery...
This is a federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $82,041.50 firm-fixed-price delivery order contract is for the supply of KEYTRUDA 100 MG/4 ML VIAL 4ML, a pharmaceutical product. This award is not associated with a set-aside designation. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, provides for the delivery of Keytruda 100 mg/4 ml vial, a cancer medication, to the Defense Logistics Agency (DLA). The $32,114.28 firm fixed-price delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. This IDC allows the DLA to issue delivery orders for a wide range of...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of Keytruda 100 mg/4 ml vial (4 ml) to the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The award, valued at $96,342.84, is a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of medications and medical supplies to support the...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) for the delivery of Keytruda 100 mg/4 ml vial 4 ml. The $77,505.20 firm-fixed-price delivery order contract has a completion date of January 31, 2023. DMS Pharmaceutical Group is a key pharmaceutical supplier to the U.S. Department of Defense, having secured a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program to provide a...
This federal contract award, valued at $80,218.40, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is a firm fixed-price delivery order for the supply of Keytruda 100 mg/4 ml vial 4 ml, a specialized oncology medication, to support the recurring medical supply needs of military health facilities. The award is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the...